In the Claims:

Please amend the claims as follows:

1. (Currently amended) A pharmaceutical composition for reducing angiogenesis in tumor cells, the method comprising

monoclonal anti-CD66a 4D1/C2 antibody which was deposited with DSMZ (German-Type Collection of Microorganisms and Cell Cultures) Braunschweig under DSM ACC2371 on October 22, and a pharmaceutically compatible carrier, wherein the monoclonal anti-CD66a 4D1/C2 antibody is in an a therapeutically active effective amount to reduce formation of capillaries in the tumor cells by functionally blocking CD66a on tumor endothelial cell.

- 2. (Previously presented) The composition according to claim 1, characterized in that the monoclonal anti-CD66a 4D1/C2 antibody which functionally blocks CD66a binds specifically to one or more functional domains of CD66a.
- 3. (Previously cancelled)
- 4. (Previously cancelled)
- 5. (Withdrawn) The composition according to claim 1(b), characterized in that the substances which inhibit the expression of CD66a or CD66a ligand are anti-sense oligonucleotides or anti-sense RNA.
- 6. (Currently amended) The composition according to claim $\underline{1}$ -4, characterized in that it is capable of <u>reducing</u> stopping tumor angiogenesis of lung cancer, breast cancer and colon carcinoma.
- 7. (Withdrawn) The composition according to claim 1(a), characterized in that the substances inducing the expression of CD66a or CD66a ligand are DNA coding for CD66a, Cd66a isoforms or CD66a fragments.

- 8. (Currently amended) A pharmaceutical composition for inhibiting *in vitro* angiogenesis in <u>tumor cells</u>, comprising <u>a</u> monoclonal anti-CD66a 4D1/C2 antibody which was deposited with DSMZ (German-Type Collection of Microorganisms and Cell Cultures) Braunschweig under DSM ACC2371 on October 22, 1998 <u>and a pharmaceutically compatible carrier</u>, wherein the monoclonal anti-CD66a 4D1/C2 antibody is in an effective amount to reduce formation of capillaries in <u>tumor</u> cell cultures by functionally blocking CD66a <u>receptor on tumor endothelial cells</u>.
- 9. (Previously presented) A method for inhibiting formation of capillaries comprising: introducing the composition of claim 1 into a tumor cell.
- 10. (Previously presented) A method for inhibiting formation of capillaries in cell cultures comprising: introducing the composition of claim 8 into a tumor cell.